{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semax-trigeminal","title":"Semax for Trigeminal Neuralgia: Evidence-Graded Review","body":"## What's breaking down\nTrigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. The result is sudden, electric-shock-like facial pain. Over time the system tips toward degeneration when repair signals like neurotrophic factors fall short of the ongoing mechanical or inflammatory stress.\n\n## Why Semax might help you\n1. **What keeps failing:** Neural support pathways weaken under sustained trigeminal nerve stress, with reduced BDNF signaling that normally aids neuron survival and myelin maintenance.\n2. **What Semax is studied to do:** Semax is examined for raising BDNF protein and gene expression plus supporting neuronal resilience without directly blocking pain signals.\n3. **Therefore for you:** If the neural repair layer contributes to your trigeminal issue, Semax enters discussion because it targets building connections and resilience rather than suppressing symptoms.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If a broader stack appears later, other agents would address separate layers such as inflammation or mechanical load.\n\n## What the evidence actually shows\nHuman data: One study of 110 post-stroke patients found semax (two 10-day courses at 6000 mcg/day) raised plasma BDNF levels regardless of rehabilitation timing and correlated with faster motor recovery (Gusev et al., 2018, human|preclinical-adjacent). A separate resting-state fMRI trial in 24 healthy volunteers showed semax altered default-mode network volume after intranasal dosing (Lebedeva et al., 2018, human).\n\nPreclinical data: Rat hippocampal studies demonstrated single-dose semax increased BDNF protein 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanied by more conditioned avoidance responses (Dolotov et al., 2006, preclinical). Another rat study linked semax to rapid induction of Bdnf and Ngf mRNAs (Dmitrieva et al., 2009, preclinical).\n\nTrigeminal-specific data: No published human trials exist. FDA Pharmacy Compounding Advisory Committee materials note ongoing review of semax for possible compounding use in trigeminal neuralgia based on general neuroprotective effects; published evidence for this exact indication remains thin (healingmaps.com summary, 2026, mechanistic).\n\n## What scientists say\nResearchers describe semax as an ACTH(4-10) analog that modulates neurotrophin expression and shows neuroprotective actions in hypoxia and glutamate toxicity models. Emphasis stays on BDNF/trkB pathway engagement and cognitive or recovery support rather than primary analgesia (multiple PubMed-linked abstracts, preclinical to early human).\n\n## What people say on Reddit\nUsers mention semax in passing for various nerve-related complaints. One thread notes possible benefit in occipital neuralgia but states trigeminal neuralgia behaves differently. Another speculates it could worsen certain nerve pain or questions its relevance. Anecdotal reports remain sparse and mixed (r/Nootropics threads, anecdotal).\n\n## What people say on X\nPublic posts referencing semax and trigeminal issues are rare. Discussions usually stay at the level of general nootropic interest or FDA compounding updates rather than personal outcome reports (anecdotal).\n\n## What we do not know\nNo randomized controlled trials exist for semax in trigeminal neuralgia. Long-term human safety data beyond short stroke-rehabilitation courses are limited. Whether BDNF changes translate to reduced trigeminal ectopic firing in humans is unknown. Dose-response, optimal route, and interaction with common trigeminal medications remain unstudied in this population.\n\n## Safety and limits\nReported human use in stroke studies showed no major adverse events during the described regimens. Individual responses vary. Semax remains unapproved by FDA for trigeminal neuralgia; any consideration occurs under compounding review scheduled for 2026. Always consult qualified clinicians for personal medical decisions.\n","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-trigeminal/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax raised plasma BDNF levels in 110 post-ischemic stroke patients and correlated with faster functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human trial data separating BDNF effect from placebo or standard care.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Intranasal semax altered default-mode network volume on fMRI in healthy volunteers within 20 minutes.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Objective imaging endpoint in non-patient population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"In rats, semax increased hippocampal BDNF protein 1.4-fold and BDNF mRNA up to 3-fold within hours of dosing.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Controlled animal experiment quantifying neurotrophin changes.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human clinical trials test semax specifically for trigeminal neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"FDA review documents note absence of indication-specific trials.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Semax is under FDA Pharmacy Compounding Advisory Committee review for possible inclusion on the 503A Bulks List for trigeminal neuralgia based on neuroprotective properties.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Regulatory context explains current interest without clinical outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report anecdotal observations of semax with occipital neuralgia but distinguish trigeminal neuralgia as potentially different.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"User-generated discussion threads.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period.","summary":"110-patient stroke cohort; semax raised BDNF and improved motor/Barthel scores.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"85ab861514ed31cc4f7ec006f2b15fb33c18e2b93904f86d63b1abbb0c484d23"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/30225715/","title":"Effects of Semax on the Default Mode Network of the Brain","quote":"A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls.","summary":"fMRI study in 24 healthy volunteers showing network changes post-intranasal semax.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"verified","prev":"85ab861514ed31cc4f7ec006f2b15fb33c18e2b93904f86d63b1abbb0c484d23","hash":"8df4bc6b96ae203d1f8cbdc36f0355afb000eafb9382f6b2adc4fc562ff04305"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax (50 μg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels... and a 3-fold... increase of exon III BDNF... mRNA levels","summary":"Rat study quantifying rapid BDNF/trkB upregulation and behavioral change.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"unverified","prev":"8df4bc6b96ae203d1f8cbdc36f0355afb000eafb9382f6b2adc4fc562ff04305","hash":"7ea34e9ba093fa14583918fb34dffddc2df9d532bed849dfaa81fcd95fe9138e"},{"id":"s4","type":"news","url":"https://healingmaps.com/semax-peptide-cerebral-ischemia-migraine-trigeminal-neuralgia/","title":"Semax: The Russian Nootropic Peptide Under FDA Review","quote":"Published evidence for this specific indication is thin but the clinical need is real, and PCAC will examine whether the available data supports compounding for this use.","summary":"Summarizes FDA compounding review context for trigeminal neuralgia.","claim_ids":["c4","c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"verified","prev":"7ea34e9ba093fa14583918fb34dffddc2df9d532bed849dfaa81fcd95fe9138e","hash":"d958c88611babbb719933348fee1862ae566fefda099401ea3c78be494fe181c"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Nootropics/comments/5h3d77/giving_semax_to_my_elderly_father_hes_had_a/","title":"Giving Semax to my elderly father?","quote":"It helped pretty much immediately with my occipital neuralgia pain, but trigeminal neuralgia is a different beast.","summary":"Anecdotal user comment distinguishing neuralgia subtypes.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"unverified","prev":"d958c88611babbb719933348fee1862ae566fefda099401ea3c78be494fe181c","hash":"848d8843c06bcb3cb70359b36b32cf30815e2262e73e3d32ab91ec1aa1998941"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:01:13.598Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Trigeminal Neuralgia: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\nTrigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. The result is sudden, electric-shock-like facial pain. Over time the system tips toward degeneration when repair signals like neurotrophic factors fall short of the ongoing mechanical or inflammatory stress.\n\n## Why Semax might help you\n1. **What keeps failing:** Neural support pathways weaken under sustained trigeminal nerve stress, with reduced BDNF signaling that normally aids neuron survival and myelin maintenance.\n2. **What Semax is studied to do:** Semax is examined for raising BDNF protein and gene expression plus supporting neuronal resilience without directly blocking pain signals.\n3. **Therefore for you:** If the neural repair layer contributes to your trigeminal issue, Semax enters discussion because it targets building connections and resilience rather than suppressing symptoms.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If a broader stack appears later, other agents would address separate layers such as inflammation or mechanical load.\n\n## What the evidence actually shows\nHuman data: One study of 110 post-stroke patients found semax (two 10-day courses at 6000 mcg/day) raised plasma BDNF levels regardless of rehabilitation timing and correlated with faster motor recovery (Gusev et al., 2018, human|preclinical-adjacent). A separate resting-state fMRI trial in 24 healthy volunteers showed semax altered default-mode network volume after intranasal dosing (Lebedeva et al., 2018, human).\n\nPreclinical data: Rat hippocampal studies demonstrated single-dose semax increased BDNF protein 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanied by more conditioned avoidance responses (Dolotov et al., 2006, preclinical). Another rat study linked semax to rapid induction of Bdnf and Ngf mRNAs (Dmitrieva et al., 2009, preclinical).\n\nTrigeminal-specific data: No published human trials exist. FDA Pharmacy Compounding Advisory Committee materials note ongoing review of semax for possible compounding use in trigeminal neuralgia based on general neuroprotective effects; published evidence for this exact indication remains thin (healingmaps.com summary, 2026, mechanistic).\n\n## What scientists say\nResearchers describe semax as an ACTH(4-10) analog that modulates neurotrophin expression and shows neuroprotective actions in hypoxia and glutamate toxicity models. Emphasis stays on BDNF/trkB pathway engagement and cognitive or recovery support rather than primary analgesia (multiple PubMed-linked abstracts, preclinical to early human).\n\n## What people say on Reddit\nUsers mention semax in passing for various nerve-related complaints. One thread notes possible benefit in occipital neuralgia but states trigeminal neuralgia behaves differently. Another speculates it could worsen certain nerve pain or questions its relevance. Anecdotal reports remain sparse and mixed (r/Nootropics threads, anecdotal).\n\n## What people say on X\nPublic posts referencing semax and trigeminal issues are rare. Discussions usually stay at the level of general nootropic interest or FDA compounding updates rather than personal outcome reports (anecdotal).\n\n## What we do not know\nNo randomized controlled trials exist for semax in trigeminal neuralgia. Long-term human safety data beyond short stroke-rehabilitation courses are limited. Whether BDNF changes translate to reduced trigeminal ectopic firing in humans is unknown. Dose-response, optimal route, and interaction with common trigeminal medications remain unstudied in this population.\n\n## Safety and limits\nReported human use in stroke studies showed no major adverse events during the described regimens. Individual responses vary. Semax remains unapproved by FDA for trigeminal neuralgia; any consideration occurs under compounding review scheduled for 2026. Always consult qualified clinicians for personal medical decisions.\n","claims":[{"id":"c1","text":"Semax raised plasma BDNF levels in 110 post-ischemic stroke patients and correlated with faster functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human trial data separating BDNF effect from placebo or standard care.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Intranasal semax altered default-mode network volume on fMRI in healthy volunteers within 20 minutes.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Objective imaging endpoint in non-patient population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"In rats, semax increased hippocampal BDNF protein 1.4-fold and BDNF mRNA up to 3-fold within hours of dosing.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Controlled animal experiment quantifying neurotrophin changes.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human clinical trials test semax specifically for trigeminal neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"FDA review documents note absence of indication-specific trials.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Semax is under FDA Pharmacy Compounding Advisory Committee review for possible inclusion on the 503A Bulks List for trigeminal neuralgia based on neuroprotective properties.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Regulatory context explains current interest without clinical outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report anecdotal observations of semax with occipital neuralgia but distinguish trigeminal neuralgia as potentially different.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"User-generated discussion threads.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/30225715/","title":"Effects of Semax on the Default Mode Network of the Brain","quote":"A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax (50 μg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels... and a 3-fold... increase of exon III BDNF... mRNA levels","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"news","url":"https://healingmaps.com/semax-peptide-cerebral-ischemia-migraine-trigeminal-neuralgia/","title":"Semax: The Russian Nootropic Peptide Under FDA Review","quote":"Published evidence for this specific indication is thin but the clinical need is real, and PCAC will examine whether the available data supports compounding for this use.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Nootropics/comments/5h3d77/giving_semax_to_my_elderly_father_hes_had_a/","title":"Giving Semax to my elderly father?","quote":"It helped pretty much immediately with my occipital neuralgia pain, but trigeminal neuralgia is a different beast.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":13792,"tokens_out":2902,"cost":0.024495,"prev_hash":"genesis","hash":"b745ff26a1d500c4578773ffacf4f166a62a27059cacb07e7875494a359712b1"}],"provenance":[{"ts":"2026-06-30T00:01:13.598Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Trigeminal\nSlug: semax-trigeminal\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n2. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n3. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other la","response":"{\"slug\":\"semax-trigeminal\",\"title\":\"Semax for Trigeminal Neuralgia: Evidence-Graded Review\",\"body\":\"## What's breaking down\\nTrigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. The result is sudden, electric-shock-like facial pain. Over time the system tips toward degeneration when repair signals like neurotrophic factors fall short of the ongoing mechanical or inflammatory stress.\\n\\n## Why Semax might help you\\n1. **What keeps failing:** Neural support pathways weaken under sustained trigeminal nerve stress, with reduced BDNF signaling that normally aids neuron survival and myelin maintenance.\\n2. **What Semax is studied to do:** Semax is examined for raising BDNF protein and gene expression plus supporting neuronal resilience without directly blocking pain signals.\\n3. **Therefore for you:** If the neural repair layer contributes to your trigeminal issue, Semax enters discussion because it targets building connections and resilience rather than suppressing symptoms.\\n\\n## How these fit together\\nSingle-compound focus. Semax maps to the neural repair layer. If a broader stack appears later, other agents would address separate layers such as inflammation or mechanical load.\\n\\n## What the evidence actually shows\\nHuman data: One study of 110 post-stroke patients found semax (two 10-day courses at 6000 mcg/day) raised plasma BDNF levels regardless of rehabilitation timing and correlated with faster motor recovery (Gusev et al., 2018, human|preclinical-adjacent). A separate resting-state fMRI trial in 24 healthy volunteers showed semax altered default-mode network volume after intranasal dosing (Lebedeva et al., 2018, human).\\n\\nPreclinical data: Rat hippocampal studies demonstrated single-dose semax increased BDNF protein 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanie","tokens_in":13792,"tokens_out":2902,"cost":0,"prev":"genesis","hash":"73f1e7c50b6e774c7820340988e3850488ca8361b25c7658a2eb2181cdaa2fc6"},{"ts":"2026-07-17T02:41:59.551Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-trigeminal","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"73f1e7c50b6e774c7820340988e3850488ca8361b25c7658a2eb2181cdaa2fc6","hash":"4267aedf7147add7c7ef7cb5e16ffc47a1415e07f8375bd487b6122e81c46a0f"}],"energy":{"passes":2,"tokens_in":13792,"tokens_out":2902,"tokens_total":16694,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"4267aedf7147add7c7ef7cb5e16ffc47a1415e07f8375bd487b6122e81c46a0f"},"posted_at":"2026-06-29T21:33:19.934Z","created_at":"2026-06-29T21:33:19.934Z","updated_at":"2026-07-17T02:41:59.551Z","machine":{"shape":"article.machine/v1","slug":"semax-trigeminal","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-trigeminal","json":"https://miscsubjects.com/api/articles/semax-trigeminal","bundle":"https://miscsubjects.com/api/articles/semax-trigeminal/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semax-trigeminal/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-trigeminal","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-trigeminal\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-trigeminal\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-trigeminal/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-trigeminal\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-trigeminal | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-trigeminal","json":"/api/articles/semax-trigeminal","markdown":"/api/articles/semax-trigeminal/bundle?format=markdown","skill":"/api/articles/semax-trigeminal/skill","topology":"/api/articles/semax-trigeminal/topology","versions":"/api/articles/semax-trigeminal/revisions","invocations":"/api/articles/semax-trigeminal/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-trigeminal","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"004847fd4e788e6e8590b46ee52d21227138e1ae0d55780f801fc857ceb63bcd","object":{"object_type":"article-object","identity":{"id":"article:semax-trigeminal","slug":"semax-trigeminal","title":"Semax for Trigeminal Neuralgia: Evidence-Graded Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semax-trigeminal","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semax-trigeminal/skill","role":"direct behavior","audience":"model","content":"---\nname: semax-trigeminal\ndescription: Apply the Semax for Trigeminal Neuralgia: Evidence-Graded Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Semax for Trigeminal Neuralgia: Evidence-Graded Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/semax-trigeminal). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semax-trigeminal.\n- Read claims and relationships at /api/articles/semax-trigeminal/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Trigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. T\n\n## Representations\n\n- Human: /a/semax-trigeminal\n- JSON: /api/articles/semax-trigeminal\n- Relationships: /api/articles/semax-trigeminal/topology\n- History: /api/articles/semax-trigeminal/revisions\n"},"json":{"route":"/api/articles/semax-trigeminal","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semax-trigeminal/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","semax","trigeminal"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semax-trigeminal/invocations?status=success","failure_events":"/api/articles/semax-trigeminal/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semax-trigeminal","title":"Semax for Trigeminal Neuralgia: Evidence-Graded Review","body":"## What's breaking down\nTrigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. The result is sudden, electric-shock-like facial pain. Over time the system tips toward degeneration when repair signals like neurotrophic factors fall short of the ongoing mechanical or inflammatory stress.\n\n## Why Semax might help you\n1. **What keeps failing:** Neural support pathways weaken under sustained trigeminal nerve stress, with reduced BDNF signaling that normally aids neuron survival and myelin maintenance.\n2. **What Semax is studied to do:** Semax is examined for raising BDNF protein and gene expression plus supporting neuronal resilience without directly blocking pain signals.\n3. **Therefore for you:** If the neural repair layer contributes to your trigeminal issue, Semax enters discussion because it targets building connections and resilience rather than suppressing symptoms.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If a broader stack appears later, other agents would address separate layers such as inflammation or mechanical load.\n\n## What the evidence actually shows\nHuman data: One study of 110 post-stroke patients found semax (two 10-day courses at 6000 mcg/day) raised plasma BDNF levels regardless of rehabilitation timing and correlated with faster motor recovery (Gusev et al., 2018, human|preclinical-adjacent). A separate resting-state fMRI trial in 24 healthy volunteers showed semax altered default-mode network volume after intranasal dosing (Lebedeva et al., 2018, human).\n\nPreclinical data: Rat hippocampal studies demonstrated single-dose semax increased BDNF protein 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanied by more conditioned avoidance responses (Dolotov et al., 2006, preclinical). Another rat study linked semax to rapid induction of Bdnf and Ngf mRNAs (Dmitrieva et al., 2009, preclinical).\n\nTrigeminal-specific data: No published human trials exist. FDA Pharmacy Compounding Advisory Committee materials note ongoing review of semax for possible compounding use in trigeminal neuralgia based on general neuroprotective effects; published evidence for this exact indication remains thin (healingmaps.com summary, 2026, mechanistic).\n\n## What scientists say\nResearchers describe semax as an ACTH(4-10) analog that modulates neurotrophin expression and shows neuroprotective actions in hypoxia and glutamate toxicity models. Emphasis stays on BDNF/trkB pathway engagement and cognitive or recovery support rather than primary analgesia (multiple PubMed-linked abstracts, preclinical to early human).\n\n## What people say on Reddit\nUsers mention semax in passing for various nerve-related complaints. One thread notes possible benefit in occipital neuralgia but states trigeminal neuralgia behaves differently. Another speculates it could worsen certain nerve pain or questions its relevance. Anecdotal reports remain sparse and mixed (r/Nootropics threads, anecdotal).\n\n## What people say on X\nPublic posts referencing semax and trigeminal issues are rare. Discussions usually stay at the level of general nootropic interest or FDA compounding updates rather than personal outcome reports (anecdotal).\n\n## What we do not know\nNo randomized controlled trials exist for semax in trigeminal neuralgia. Long-term human safety data beyond short stroke-rehabilitation courses are limited. Whether BDNF changes translate to reduced trigeminal ectopic firing in humans is unknown. Dose-response, optimal route, and interaction with common trigeminal medications remain unstudied in this population.\n\n## Safety and limits\nReported human use in stroke studies showed no major adverse events during the described regimens. Individual responses vary. Semax remains unapproved by FDA for trigeminal neuralgia; any consideration occurs under compounding review scheduled for 2026. Always consult qualified clinicians for personal medical decisions.\n","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-trigeminal/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax raised plasma BDNF levels in 110 post-ischemic stroke patients and correlated with faster functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human trial data separating BDNF effect from placebo or standard care.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Intranasal semax altered default-mode network volume on fMRI in healthy volunteers within 20 minutes.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Objective imaging endpoint in non-patient population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"In rats, semax increased hippocampal BDNF protein 1.4-fold and BDNF mRNA up to 3-fold within hours of dosing.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Controlled animal experiment quantifying neurotrophin changes.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human clinical trials test semax specifically for trigeminal neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"FDA review documents note absence of indication-specific trials.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Semax is under FDA Pharmacy Compounding Advisory Committee review for possible inclusion on the 503A Bulks List for trigeminal neuralgia based on neuroprotective properties.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Regulatory context explains current interest without clinical outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report anecdotal observations of semax with occipital neuralgia but distinguish trigeminal neuralgia as potentially different.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"User-generated discussion threads.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period.","summary":"110-patient stroke cohort; semax raised BDNF and improved motor/Barthel scores.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"85ab861514ed31cc4f7ec006f2b15fb33c18e2b93904f86d63b1abbb0c484d23"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/30225715/","title":"Effects of Semax on the Default Mode Network of the Brain","quote":"A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls.","summary":"fMRI study in 24 healthy volunteers showing network changes post-intranasal semax.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"verified","prev":"85ab861514ed31cc4f7ec006f2b15fb33c18e2b93904f86d63b1abbb0c484d23","hash":"8df4bc6b96ae203d1f8cbdc36f0355afb000eafb9382f6b2adc4fc562ff04305"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax (50 μg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels... and a 3-fold... increase of exon III BDNF... mRNA levels","summary":"Rat study quantifying rapid BDNF/trkB upregulation and behavioral change.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"unverified","prev":"8df4bc6b96ae203d1f8cbdc36f0355afb000eafb9382f6b2adc4fc562ff04305","hash":"7ea34e9ba093fa14583918fb34dffddc2df9d532bed849dfaa81fcd95fe9138e"},{"id":"s4","type":"news","url":"https://healingmaps.com/semax-peptide-cerebral-ischemia-migraine-trigeminal-neuralgia/","title":"Semax: The Russian Nootropic Peptide Under FDA Review","quote":"Published evidence for this specific indication is thin but the clinical need is real, and PCAC will examine whether the available data supports compounding for this use.","summary":"Summarizes FDA compounding review context for trigeminal neuralgia.","claim_ids":["c4","c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"verified","prev":"7ea34e9ba093fa14583918fb34dffddc2df9d532bed849dfaa81fcd95fe9138e","hash":"d958c88611babbb719933348fee1862ae566fefda099401ea3c78be494fe181c"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Nootropics/comments/5h3d77/giving_semax_to_my_elderly_father_hes_had_a/","title":"Giving Semax to my elderly father?","quote":"It helped pretty much immediately with my occipital neuralgia pain, but trigeminal neuralgia is a different beast.","summary":"Anecdotal user comment distinguishing neuralgia subtypes.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:01:08.010Z","link_status":"ok","quote_status":"unverified","prev":"d958c88611babbb719933348fee1862ae566fefda099401ea3c78be494fe181c","hash":"848d8843c06bcb3cb70359b36b32cf30815e2262e73e3d32ab91ec1aa1998941"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:01:13.598Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Trigeminal Neuralgia: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\nTrigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. The result is sudden, electric-shock-like facial pain. Over time the system tips toward degeneration when repair signals like neurotrophic factors fall short of the ongoing mechanical or inflammatory stress.\n\n## Why Semax might help you\n1. **What keeps failing:** Neural support pathways weaken under sustained trigeminal nerve stress, with reduced BDNF signaling that normally aids neuron survival and myelin maintenance.\n2. **What Semax is studied to do:** Semax is examined for raising BDNF protein and gene expression plus supporting neuronal resilience without directly blocking pain signals.\n3. **Therefore for you:** If the neural repair layer contributes to your trigeminal issue, Semax enters discussion because it targets building connections and resilience rather than suppressing symptoms.\n\n## How these fit together\nSingle-compound focus. Semax maps to the neural repair layer. If a broader stack appears later, other agents would address separate layers such as inflammation or mechanical load.\n\n## What the evidence actually shows\nHuman data: One study of 110 post-stroke patients found semax (two 10-day courses at 6000 mcg/day) raised plasma BDNF levels regardless of rehabilitation timing and correlated with faster motor recovery (Gusev et al., 2018, human|preclinical-adjacent). A separate resting-state fMRI trial in 24 healthy volunteers showed semax altered default-mode network volume after intranasal dosing (Lebedeva et al., 2018, human).\n\nPreclinical data: Rat hippocampal studies demonstrated single-dose semax increased BDNF protein 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanied by more conditioned avoidance responses (Dolotov et al., 2006, preclinical). Another rat study linked semax to rapid induction of Bdnf and Ngf mRNAs (Dmitrieva et al., 2009, preclinical).\n\nTrigeminal-specific data: No published human trials exist. FDA Pharmacy Compounding Advisory Committee materials note ongoing review of semax for possible compounding use in trigeminal neuralgia based on general neuroprotective effects; published evidence for this exact indication remains thin (healingmaps.com summary, 2026, mechanistic).\n\n## What scientists say\nResearchers describe semax as an ACTH(4-10) analog that modulates neurotrophin expression and shows neuroprotective actions in hypoxia and glutamate toxicity models. Emphasis stays on BDNF/trkB pathway engagement and cognitive or recovery support rather than primary analgesia (multiple PubMed-linked abstracts, preclinical to early human).\n\n## What people say on Reddit\nUsers mention semax in passing for various nerve-related complaints. One thread notes possible benefit in occipital neuralgia but states trigeminal neuralgia behaves differently. Another speculates it could worsen certain nerve pain or questions its relevance. Anecdotal reports remain sparse and mixed (r/Nootropics threads, anecdotal).\n\n## What people say on X\nPublic posts referencing semax and trigeminal issues are rare. Discussions usually stay at the level of general nootropic interest or FDA compounding updates rather than personal outcome reports (anecdotal).\n\n## What we do not know\nNo randomized controlled trials exist for semax in trigeminal neuralgia. Long-term human safety data beyond short stroke-rehabilitation courses are limited. Whether BDNF changes translate to reduced trigeminal ectopic firing in humans is unknown. Dose-response, optimal route, and interaction with common trigeminal medications remain unstudied in this population.\n\n## Safety and limits\nReported human use in stroke studies showed no major adverse events during the described regimens. Individual responses vary. Semax remains unapproved by FDA for trigeminal neuralgia; any consideration occurs under compounding review scheduled for 2026. Always consult qualified clinicians for personal medical decisions.\n","claims":[{"id":"c1","text":"Semax raised plasma BDNF levels in 110 post-ischemic stroke patients and correlated with faster functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human trial data separating BDNF effect from placebo or standard care.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Intranasal semax altered default-mode network volume on fMRI in healthy volunteers within 20 minutes.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Objective imaging endpoint in non-patient population.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"In rats, semax increased hippocampal BDNF protein 1.4-fold and BDNF mRNA up to 3-fold within hours of dosing.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Controlled animal experiment quantifying neurotrophin changes.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No published human clinical trials test semax specifically for trigeminal neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"FDA review documents note absence of indication-specific trials.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Semax is under FDA Pharmacy Compounding Advisory Committee review for possible inclusion on the 503A Bulks List for trigeminal neuralgia based on neuroprotective properties.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Regulatory context explains current interest without clinical outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users report anecdotal observations of semax with occipital neuralgia but distinguish trigeminal neuralgia as potentially different.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"User-generated discussion threads.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:01:13.195Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","title":"The efficacy of semax in the treatment of patients at different stages of ischemic stroke","quote":"Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/30225715/","title":"Effects of Semax on the Default Mode Network of the Brain","quote":"A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","title":"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus","quote":"a single application of Semax (50 μg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels... and a 3-fold... increase of exon III BDNF... mRNA levels","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"news","url":"https://healingmaps.com/semax-peptide-cerebral-ischemia-migraine-trigeminal-neuralgia/","title":"Semax: The Russian Nootropic Peptide Under FDA Review","quote":"Published evidence for this specific indication is thin but the clinical need is real, and PCAC will examine whether the available data supports compounding for this use.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Nootropics/comments/5h3d77/giving_semax_to_my_elderly_father_hes_had_a/","title":"Giving Semax to my elderly father?","quote":"It helped pretty much immediately with my occipital neuralgia pain, but trigeminal neuralgia is a different beast.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":13792,"tokens_out":2902,"cost":0.024495,"prev_hash":"genesis","hash":"b745ff26a1d500c4578773ffacf4f166a62a27059cacb07e7875494a359712b1"}],"provenance":[{"ts":"2026-06-30T00:01:13.598Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Trigeminal\nSlug: semax-trigeminal\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n2. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n3. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other la","response":"{\"slug\":\"semax-trigeminal\",\"title\":\"Semax for Trigeminal Neuralgia: Evidence-Graded Review\",\"body\":\"## What's breaking down\\nTrigeminal neuralgia involves irritation or damage along the trigeminal nerve pathways. This can include focal demyelination, vascular compression, or chronic low-grade inflammation that triggers ectopic nerve firing. The result is sudden, electric-shock-like facial pain. Over time the system tips toward degeneration when repair signals like neurotrophic factors fall short of the ongoing mechanical or inflammatory stress.\\n\\n## Why Semax might help you\\n1. **What keeps failing:** Neural support pathways weaken under sustained trigeminal nerve stress, with reduced BDNF signaling that normally aids neuron survival and myelin maintenance.\\n2. **What Semax is studied to do:** Semax is examined for raising BDNF protein and gene expression plus supporting neuronal resilience without directly blocking pain signals.\\n3. **Therefore for you:** If the neural repair layer contributes to your trigeminal issue, Semax enters discussion because it targets building connections and resilience rather than suppressing symptoms.\\n\\n## How these fit together\\nSingle-compound focus. Semax maps to the neural repair layer. If a broader stack appears later, other agents would address separate layers such as inflammation or mechanical load.\\n\\n## What the evidence actually shows\\nHuman data: One study of 110 post-stroke patients found semax (two 10-day courses at 6000 mcg/day) raised plasma BDNF levels regardless of rehabilitation timing and correlated with faster motor recovery (Gusev et al., 2018, human|preclinical-adjacent). A separate resting-state fMRI trial in 24 healthy volunteers showed semax altered default-mode network volume after intranasal dosing (Lebedeva et al., 2018, human).\\n\\nPreclinical data: Rat hippocampal studies demonstrated single-dose semax increased BDNF protein 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanie","tokens_in":13792,"tokens_out":2902,"cost":0,"prev":"genesis","hash":"73f1e7c50b6e774c7820340988e3850488ca8361b25c7658a2eb2181cdaa2fc6"},{"ts":"2026-07-17T02:41:59.551Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-trigeminal","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"73f1e7c50b6e774c7820340988e3850488ca8361b25c7658a2eb2181cdaa2fc6","hash":"4267aedf7147add7c7ef7cb5e16ffc47a1415e07f8375bd487b6122e81c46a0f"}],"energy":{"passes":2,"tokens_in":13792,"tokens_out":2902,"tokens_total":16694,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"4267aedf7147add7c7ef7cb5e16ffc47a1415e07f8375bd487b6122e81c46a0f"},"posted_at":"2026-06-29T21:33:19.934Z","created_at":"2026-06-29T21:33:19.934Z","updated_at":"2026-07-17T02:41:59.551Z","machine":{"shape":"article.machine/v1","slug":"semax-trigeminal","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-trigeminal","json":"https://miscsubjects.com/api/articles/semax-trigeminal","bundle":"https://miscsubjects.com/api/articles/semax-trigeminal/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semax-trigeminal/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-trigeminal","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-trigeminal\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-trigeminal\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-trigeminal/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-trigeminal\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-trigeminal | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-trigeminal","json":"/api/articles/semax-trigeminal","markdown":"/api/articles/semax-trigeminal/bundle?format=markdown","skill":"/api/articles/semax-trigeminal/skill","topology":"/api/articles/semax-trigeminal/topology","versions":"/api/articles/semax-trigeminal/revisions","invocations":"/api/articles/semax-trigeminal/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-trigeminal","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"004847fd4e788e6e8590b46ee52d21227138e1ae0d55780f801fc857ceb63bcd"}}}